Table 1.
Outline of the In Vivo Study Design
| Study | Study Size, | Delivery | Injection Volume | Dose* | Study Duration | PK Timepoints |
|---|---|---|---|---|---|---|
| Number | Species | Route | (Concentration) | (mg/Eye) | (Weeks) | After the Dose |
| 1 | n = 10 male NZW rabbits | IVT SC | 0.025 mL (4 mg/mL) 0.1 mL (10 mg/mL) | 1 1 | 1 | 0.08, 6, 24, 72, and 168 hours |
| 2 | n = 14 male DB rabbits | SC | 0.1 mL (40 mg/mL) | 4 | 13 | 2, 4, 8, 15, 29, 61, and 91days |
| 3 | n = 14 male DB rabbits | SC | 0.1 mL (1 mg/mL) 0.1 mL (0.3 mg/mL) | 0.1 0.03 | 10 | 2, 8, 15, 31, 45, 61, and 66 (±1) days |
NZW, New Zealand White; DB, Dutch Belted.
Both eyes of each animal were dosed. All animals were free of ophthalmologic abnormalities before test article administration, assessed by a board-certified veterinary ophthalmologist using a slit lamp biomicroscope and an indirect ophthalmoscope.